Michael Rome
Directeur/Membre du Conseil chez Remix Therapeutics, Inc.
Profil
Michael Rome is currently a Managing Director at Foresite Capital Management LLC, a Director at Remix Therapeutics, Inc., a Director at Pharvaris GmbH, a Director at Alumis, Inc., and a Director at XinThera, Inc. He previously worked as a Director at Maze Therapeutics, Inc.
Postes actifs de Michael Rome
| Sociétés | Poste | Début |
|---|---|---|
Foresite Capital Management LLC
 Foresite Capital Management LLC Investment ManagersFinance Foresite Capital Management LLC (Foresite Capital) is a private equity firm founded in 2010 by James Tananbaum. The firm is headquartered in San Francisco. | Private Equity Investor | 01/01/2016 |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Directeur/Membre du Conseil | 01/07/2020 |
Remix Therapeutics, Inc.
 Remix Therapeutics, Inc. BiotechnologyHealth Technology Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
Alumis, Inc.
 Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. manufactures and sells pharmaceutical products for neuroinflammatory, neurodegenerative, and immune diseases. The company is based in San Francisco, CA. The company was founded by June H Lee. Martin Babler has been the CEO of the company since 2021. | Directeur/Membre du Conseil | - |
Xinthera, Inc.
 Xinthera, Inc. Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., XinThera, Inc. is a drug discovery company focused on building a small molecule oncology and immunology pipeline. The company is based in San Diego, CA. XinThera is backed by a group of international investors including Foresite Capital, OrbiMed Advisors, LLC, and TTM Capital. XinThera's lead programs focus on well-validated targets with a mission to rapidly create and advance fast-follower programs with potential in areas of high-unmet need. XinThera was founded by Qing Dong, Stephen W. Kaldor, and Gene Hung. The CEO is Christopher C. LeMasters. | Directeur/Membre du Conseil | 01/01/2021 |
Anciens postes connus de Michael Rome
| Sociétés | Poste | Fin |
|---|---|---|
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Foresite Capital Management LLC
Foresite Capital Management LLC Investment ManagersFinance Foresite Capital Management LLC (Foresite Capital) is a private equity firm founded in 2010 by James Tananbaum. The firm is headquartered in San Francisco. | Finance |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Commercial Services |
Pharvaris GmbH
Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Health Technology |
Remix Therapeutics, Inc.
Remix Therapeutics, Inc. BiotechnologyHealth Technology Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA. | Health Technology |
Alumis, Inc.
Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. manufactures and sells pharmaceutical products for neuroinflammatory, neurodegenerative, and immune diseases. The company is based in San Francisco, CA. The company was founded by June H Lee. Martin Babler has been the CEO of the company since 2021. | Health Technology |
Xinthera, Inc.
Xinthera, Inc. Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., XinThera, Inc. is a drug discovery company focused on building a small molecule oncology and immunology pipeline. The company is based in San Diego, CA. XinThera is backed by a group of international investors including Foresite Capital, OrbiMed Advisors, LLC, and TTM Capital. XinThera's lead programs focus on well-validated targets with a mission to rapidly create and advance fast-follower programs with potential in areas of high-unmet need. XinThera was founded by Qing Dong, Stephen W. Kaldor, and Gene Hung. The CEO is Christopher C. LeMasters. | Health Technology |
